Answers are grounded in this paper and cite their sources.
AMP-410 achieves potent antitumor efficacy with high therapeutic index and favorable tolerability in murine tumor models. It is a conditional bifunctional VEGF-4-1BB biologic designed to simultaneously neutralize VEGF and activate 4-1BB signaling, delivering a localized and dual-action approach to immunotherapy. By leveraging VEGF-dependent activation of 4-1BB, AMP-410 preferentially enhances immune responses within the tumor microenvironment, minimizing systemic toxicity while amplifying innate and adaptive immunity. In human 4-1BB transgenic mice bearing syngeneic tumors (MC38 colorectal carcinoma and B16F10 melanoma), AMP-410 promoted rapid M1 macrophage differentiation and enhanced progenitor-exhausted (Pex) T-cell signatures, suggesting coordinated activation of innate and adaptive compartments. At later stages, AMP-410 sustained macrophage antitumor activity and a continued expansion of Pex cells, consistent with long-term immune engagement. Localized activity was indicated by clonal T-cell expansion within tumors with minimal draining lymph node exchange. Compared with the systemic 4-1BB agonist urelumab in syngeneic tumor models, AMP-410 provided superior long-term protection with reduced exhaustion and improved hepatic tolerability. In head-to-head testing against a VEGF-PD-1 bispecific, AMP-410 achieved robust tumor suppression and survival benefits without systemic IFNγ surges. To establish translational relevance, VEGF concentrations were measured in tumor interstitial fluid from patients with cancer. VEGF levels were consistently two to four orders of magnitude higher in tumors than in matched serum, supporting the clinical opportunity of VEGF-restricted 4-1BB activation. Together, these studies position AMP-410 as a promising next-generation immunotherapy for both monotherapy and combination settings, with the potential to overcome key limitations of existing checkpoint- and 4-1BB-based approaches. SIGNIFICANCE: Localizing 4-1BB activity to VEGF-rich tumor microenvironments may expand the therapeutic window of 4-1BB costimulation, promoting strong antitumor immunity while limiting systemic immune activation and liver inflammation.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: